For political purposes, we want broad criteria. We cannot say that 2.5 million Americans have this illneed, that is causes this much economic damage to leave patients untreated, and that we need $250 million funding per year without using some broad criteria, because there's no way that so many patients have CCC or ICC ME.
For research purposes you want strict criteria because they make it easier to find abnormalities.
Demand SEID criteria in clinical practice, and CCC or ICC in research, with further refinement once more is known or a practical biomarker appears. That's the smart thing to do.
Disagree. I've been arguing this for years. If you argue for broad criteria you are acknowledging to anyone you can get to listen that the government numbers and stats are correct. How that's going to lead to CCC/ICC cohorts when it's near impossible to get anyone to listen to, let alone understand, the criteria issues, seems to me to be impossible. We've already seen NIH, whether accidentally, mistakenly, intentionally, or whatever, try to jam Reeves Criteria into the Nath study. They've walked it back, but can anyone really answer what that means at this point?
Although I have reason to believe our numbers have grown in recent years...let's keep in mind that the 1 million number comes from Lenny Jason's 0.4% prevalence in a 1999 paper on Fukuda. When I see 2.5 million or 4 million or 8 million I find it disturbing. If it's even 1 million that means in any random gathering of 325 people there's one with CCC/ICC ME, and that just doesn't make any sense to me.
The truth is, we deserve at least $100 million in funding, even if there are less than 500,000 of us. I don't know what the true number is. Maybe it really is a million by now, though I kind of doubt it. Regardless, I see no place to argue for broad criteria, period, end of story. Just my opinion. Mind you, I don't think the IOM report is entirely useless; it provides good arguments against those who deny the disease even exists. But there are no exclusions in the criteria and that opens the door for horrible misuse in research, never mind that it was supposed to be clinical-only anyway. It's already been used in research. I remember arguing at the time with people who said this wouldn't happen...